Terns Pharmaceuticals, Inc. Operating Income

Operating Income of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Income growth rates and interactive chart. Operating income is the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation, and cost of goods sold (COGS). Operating income–also called income from operations–takes a company's gross income, which is equivalent to total revenue minus COGS, and subtracts all operating expenses. A business's operating expenses are costs incurred from normal operating activities and include items such as office supplies and utilities. Operating income is measured before interest and tax expenses and is a good gauge of a company's operational profitability.


Highlights and Quick Summary

  • Operating Income for the quarter ending March 31, 2022 was $-13.8 Million (a -7.08% decrease compared to previous quarter)
  • Year-over-year quarterly Operating Income increased by 27.8%
  • Annual Operating Income for 2021 was $-49.9 Million (a 34.67% increase from previous year)
  • Annual Operating Income for 2020 was $-37 Million (a -47.26% decrease from previous year)
  • Twelve month Operating Income ending March 31, 2022 was $-51.4 Million (a 1.04% increase compared to previous quarter)
  • Twelve month trailing Operating Income increased by 23.47% year-over-year
Trailing Operating Income for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$-51.4 Million $-50.9 Million $-44.8 Million $-41.6 Million
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Income of Terns Pharmaceuticals, Inc.

Most recent Operating Incomeof TERN including historical data for past 10 years.

Interactive Chart of Operating Income of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Operating Income for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-13.83
2021 $-14.88 $-11.87 $-10.82 $-13.3 $-49.86
2020 $-8.77 $-8.74 $-10.1 $-9.42 $-37.03
2019 $-70.2

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.